Loading
A phase 1/2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer is a phase 1/2 interventional study registered as NCT06079112 by Mabwell (Shanghai) Bioscience Co., Ltd., with 100 participants planned, started 2023-09-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: 9MW2821 and Toripalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Toripalimab, Bladder & urothelial cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Toripalimab, Bladder & urothelial cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Toripalimab, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/